| Gene Symbol | DAO |
|---|---|
| Full Name | D-Amino Acid Oxidase |
| Chromosomal Location | 12q24.11 |
| NCBI Gene ID | 1680 |
| OMIM | 124050 |
| Ensembl ID | ENSG00000110888 |
| UniProt | P14920 |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Schizophrenia, Alzheimer's Disease, Parkinson's Disease |
| Protein Class | Flavoenzyme, Peroxisomal enzyme |
| Expression | Brain (neurons, astrocytes), liver, kidney |
DAO (D-Amino Acid Oxidase) encodes a flavin adenine dinucleotide (FAD)-dependent enzyme that catalyzes the oxidative deamination of D-amino acids. This 347-amino acid peroxisomal enzyme is primarily known for its role in metabolizing D-serine, a key endogenous NMDA receptor co-agonist critical for synaptic plasticity, learning, and memory[1]. DAO is expressed throughout the brain with particularly high levels in the cerebral cortex, hippocampus, cerebellum, and spinal cord[2].
The enzyme's activity has profound implications for neurodegenerative and psychiatric disorders. Elevated DAO activity has been documented in amyotrophic lateral sclerosis (ALS), where it contributes to D-serine depletion and subsequent NMDA receptor dysfunction[3]. Genetic variations in the DAO gene have been robustly associated with schizophrenia risk, positioning DAO as a nexus between glutamatergic signaling and psychiatric disease[4]. Recent research has also revealed connections to Alzheimer's disease and Parkinson's disease, where altered D-serine metabolism may contribute to excitotoxic mechanisms[5][6].
The human DAO gene spans approximately 18.5 kb on chromosome 12q24.11 and comprises 13 coding exons. The promoter region contains multiple regulatory elements controlling tissue-specific expression, including a peroxisome proliferator response element (PPRE) and binding sites for transcription factors involved in neuronal specification.
Multiple DAO transcript variants have been characterized:
| Variant | Description | Tissue Distribution |
|---|---|---|
| DAO-001 | Full-length canonical transcript | Brain, liver, kidney |
| DAO-002 | Alternative exon 1 usage | Brain-specific |
| DAO-003 | Truncated variant | Testis |
DAO expression is subject to epigenetic control:
DAO is a 39 kDa FAD-dependent flavoenzyme localized primarily to peroxisomes. The enzyme adopts a classical TIM-barrel fold with the active site positioned at the C-terminal end of the barrel.
DAO catalyzes the oxidative deamination of D-amino acids through a classical flavin-mediated mechanism:
While DAO can metabolize various D-amino acids, its preferred physiological substrate is D-serine. The enzyme exhibits varying affinity for:
| Brain Region | DAO Expression Level | Cell Type |
|---|---|---|
| Cerebral Cortex | High | Pyramidal neurons, astrocytes |
| Hippocampus | High | CA1-CA3 pyramidal cells |
| Cerebellum | High | Granule cells |
| Brainstem | Moderate | Motor neurons |
| Spinal Cord | High | Motor neurons |
| Basal Ganglia | Moderate | GABAergic neurons |
The primary physiological role of DAO in the brain is regulation of D-serine levels. D-serine is synthesized by serine racemase and serves as the predominant endogenous co-agonist for NMDA receptors, surpassing glycine in this role in most brain regions[7].
The DAO-D-serine relationship is crucial for:
DAO contributes to peroxisomal metabolism and cellular redox balance:
DAO's role in neurodegeneration is context-dependent:
| Condition | DAO Activity | Outcome |
|---|---|---|
| Normal aging | Moderate | Maintenance of D-serine homeostasis |
| ALS | Elevated | D-serine depletion, NMDAR dysfunction |
| Schizophrenia | Variable (genotype-dependent) | Altered NMDAR signaling |
| AD | Dysregulated | Excitotoxicity contribution |
DAO is strongly implicated in ALS pathogenesis through multiple mechanisms[3:1]:
DAO is one of the most robustly validated schizophrenia risk genes[4:1][8]:
Emerging evidence links DAO to Alzheimer's disease pathogenesis[5:1]:
DAO may contribute to Parkinson's disease through dopaminergic system effects[6:1]:
| Condition | DAO Relationship | Evidence Level |
|---|---|---|
| Epilepsy | Altered D-serine metabolism | Moderate |
| Huntington's Disease | NMDAR-mediated excitotoxicity | Preliminary |
| Bipolar Disorder | D-serine dysregulation | Moderate |
| Major Depression | DAO expression changes | Limited |
Several DAO inhibitors have been explored therapeutically[9]:
| Compound | Status | Mechanism | Challenges |
|---|---|---|---|
| Sodium Benzoate | Phase II trials | Direct DAO inhibition | Limited brain penetration |
| 3,3'-Diaminobenzidine | Preclinical | Irreversible inhibition | Toxicity |
| Phenyloxacetic acid derivatives | Preclinical | Competitive inhibition | Specificity |
| AS056 | Preclinical | Selective inhibition | Not yet in trials |
Since DAO degrades D-serine, supplementation strategies include:
Last updated: 2026-03-25
Van Vliet T, et al. DAO and NMDA receptor signaling. Neuropharmacology. 2014. ↩︎
Morikawa A, et al. D-serine metabolism in brain. J Neurochem. 2001. ↩︎
Sasabe J, et al. D-serine and D-amino acid oxidase in ALS. Ann Neurol. 2007. ↩︎ ↩︎
Burnet PW, et al. D-amino acid oxidase in schizophrenia. Schizophr Bull. 2011. ↩︎ ↩︎
Lin CH, et al. DAO polymorphisms and Alzheimer's disease. J Alzheimers Dis. 2016. ↩︎ ↩︎
Wu J, et al. D-Serine in Parkinson's disease models. Mov Disord. 2019. ↩︎ ↩︎
Mothet JP, et al. D-Serine is a key neuromodulator. Crit Rev Neurobiol. 2005. ↩︎
Straub RE, et al. DAO genetic variation and brain function. Biol Psychiatry. 2018. ↩︎
Honey LJ, et al. DAO inhibitors as therapeutic agents. J Med Chem. 2017. ↩︎